| 11.78 -0.06 (-0.51%) | 04-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 14.51 | 1-year : | 16.95 |
| Resists | First : | 12.43 | Second : | 14.51 |
| Pivot price | 11.5 |
|||
| Supports | First : | 11.26 | Second : | 10.55 |
| MAs | MA(5) : | 11.89 |
MA(20) : | 11.58  |
| MA(100) : | 11.61 |
MA(250) : | 11.64 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 67.5 |
D(3) : | 71.6 |
| RSI | RSI(14): 51.6 | |||
| 52-week | High : | 14.5 | Low : | 9.05 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ OCS ] has closed below upper band by 35.0%. Bollinger Bands are 12.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 11.81 - 11.88 | 11.88 - 11.95 |
| Low: | 11.58 - 11.66 | 11.66 - 11.75 |
| Close: | 11.65 - 11.77 | 11.77 - 11.89 |
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.
Fri, 12 Apr 2024
Short Interest in Oculis Holding AG (NASDAQ:OCS) Declines By 31.4% - MarketBeat
Tue, 09 Apr 2024
Analysts Set Oculis Holding AG (NASDAQ:OCS) Price Target at $29.29 - MarketBeat
Wed, 28 Feb 2024
Oculis advances eye treatment trials, appoints new executives - Investing.com
Wed, 28 Feb 2024
Oculis Provides Updates at R&D Day on Late-Stage Clinical Trials and Announces Key Leadership Appointments - Yahoo Finance
Wed, 21 Feb 2024
OCS Stock Quote Price and Forecast - CNN
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 37 (M) |
| Held by Insiders | 2.65e+007 (%) |
| Held by Institutions | 7.2 (%) |
| Shares Short | 39 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.573e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -6 % |
| Return on Assets (ttm) | 585.9 % |
| Return on Equity (ttm) | -37.9 % |
| Qtrly Rev. Growth | 883000 % |
| Gross Profit (p.s.) | -75.56 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -3.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -54 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | -0.2 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0.82 |
| Dividend | 0 |
| Forward Dividend | 32380 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|